Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours

Digestion. 1996:57 Suppl 1:84-5. doi: 10.1159/000201404.

Abstract

Neuroendocrine tumours of the gastroenteropancreatic system represent a therapeutic challenge. Current therapeutic strategies will be presented and discussed with especial consideration given to biotherapeutic regimens in metastatic tumour disease.

Publication types

  • Comparative Study

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Humans
  • Interferon Type I / therapeutic use*
  • Octreotide / therapeutic use*
  • Pancreatic Neoplasms / drug therapy*
  • Peptides, Cyclic / therapeutic use*
  • Recombinant Proteins
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use
  • Stomach Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Interferon Type I
  • Peptides, Cyclic
  • Recombinant Proteins
  • lanreotide
  • Somatostatin
  • Octreotide